NOVN.CH

96.21

+0.07%↑

SOON.CH

239

-0.17%↓

NOVN.CH

96.21

+0.07%↑

SOON.CH

239

-0.17%↓

NOVN.CH

96.21

+0.07%↑

SOON.CH

239

-0.17%↓

NOVN.CH

96.21

+0.07%↑

SOON.CH

239

-0.17%↓

NOVN.CH

96.21

+0.07%↑

SOON.CH

239

-0.17%↓

Search

Bachem Holding AG

Suletud

SektorTervishoid

58.85 0.77

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

56.55

Max

59.95

Põhinäitajad

By Trading Economics

Sissetulek

48M

84M

Müük

125M

365M

P/E

Sektori keskmine

35.813

50.291

Dividenditootlus

1.48

Kasumimarginaal

23.042

Töötajad

2,207

EBITDA

63M

118M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+22.66% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

1.48%

2.40%

Järgmine tulemuste avaldamine

24. juuli 2025

Turustatistika

By TradingEconomics

Turukapital

277M

4.4B

Eelmine avamishind

58.08

Eelmine sulgemishind

58.85

Uudiste sentiment

By Acuity

50%

50%

154 / 380 Pingereas Healthcare

Bachem Holding AG Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. dets 2024, 11:00 UTC

Market Talk

Bachem Has Challenging Years Ahead With Strong Capital Expenditure -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Bachem Holding AG Prognoos

Hinnasiht

By TipRanks

22.66% tõus

12 kuu keskmine prognoos

Keskmine 72 CHF  22.66%

Kõrge 78 CHF

Madal 65 CHF

Põhineb 3 Wall Streeti analüütiku instrumendi Bachem Holding AG 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

2

Osta

1

Hoia

0

Müü

Sentiment

By Acuity

154 / 380 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Bachem Holding AG

Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was founded in 1971 and is headquartered in Bubendorf, Switzerland.